Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response

• Status: Completed
• Trial end date: 2020-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure

This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Missouri-Columbia
• Collaborator: United States Department of Defense
• Treatments: Propranolol

Criteria

Inclusion Criteria:

• Autism Spectrum Disorder diagnosis

• intelligence quotient (IQ) >= 85 (if aged 15-24), >= 75 (if aged 7-14)

• Native English speaker

• Parent or caregiver must older than 18 years and be a native English speaker

Exclusion Criteria:

• Taking Alpha 2 agonists

• Non-autism learning disorder

• Other major psychiatric disorders

• Other neurological disorders

• Major head trauma

• Reaction to adhesives

• Diabetes

• Reactive airway disease

• Thyroid disease

• Bradyarrhythmias

• Unexplained syncope

• Pregnancy

• Possible interacting drugs

• Underweight (<20kg if aged 7-14 years)

• Factors affecting ability to have an MRI (if aged 15-24 years)